Could Revolution Medicines Be a Millionaire-Maker Stock?

In just three years, Revolution Medicines (RVMD) has experienced an impressive return of over 9 times its initial value. The company's shares have surged more than 130%, marking it as one of the hottest biotech stocks of 2026. The driving force behind this success is the FDA approval of its cancer therapy, Rasonque (daraxonib), for the treatment of pancreatic cancer in August 2026. This approval has attracted significant investor interest, resulting in substantial gains for early backers.

The question remains whether Revolution Medicines holds the potential to become a millionaire-maker stock in the future. While an initial investment of $990,000 could have reached the $1 million mark, a more attainable goal of growing $25,000 to $1 million would require a market cap of approximately $1.6 trillion. For context, the largest healthcare company today, Eli Lilly (LLY), currently boasts a market cap of around $1.2 trillion.

RBC Capital Markets estimates Rasonque's peak annual sales at $11.5 billion. Applying the industry average price-to-sales ratio of 8.4 to this projected sales level would estimate Revolution Medicines' market cap at around $97 billion. Furthermore, Revolution Medicines has a strong pipeline with other promising candidates, such as zoldonrasib and elironrasib, currently in different stages of clinical testing.

While the stock may not reach the $1.6 trillion threshold needed for a $25,000 investment to turn into $1 million, Revolution Medicines still presents the potential for market-beating returns. Billionaire investor Stanley Druckenmiller has recognized this potential, increasing his Duquesne Family Office's position in the biotech stock by 26.5% in the third quarter of 2026. Despite the stock's potential, it doesn't necessarily have to be a millionaire-maker to be an impressive moneymaker for long-term investors.